Ribavirin and interferon∝-2b combination therapy for 48 weeks in patients with chronic hepatitis C who either failed (non-responder) or relapsed (relapsers) from previous interferon monotherapy.

被引：0
|
作者：
Tsai, NC
Coste, A
Shimoda, N
Yee, H
Jao, R
Wong, L
Buto, S
Shimoda, S
机构：
[1] Univ Hawaii, Honolulu, HI 96822 USA
[2] St Francis Med Ctr, Honolulu, HI USA
[3] Univ Hawaii, Honolulu, HI 96822 USA
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
429
引用
收藏
页码：268A / 268A
页数：1
相关论文
共 50 条
  • [31] Consensus Interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha 2b and ribavirin in combination: An Italian pilot study.
    Barbarini, G
    Barbaro, G
    HEPATOLOGY, 2001, 34 (04) : 576A - 576A
  • [32] The combination therapy of ribavirin and pegylated interferon in non-responder, chronic HCV infection, hemodialysis patients
    Mousa, Dujanah
    Alsulaiman, Mohamad
    Alhawas, Fahad
    Alharbi, Wedad
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 197 - 197
  • [33] Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C
    August-Jörg, BSE
    Borovicka, J
    Dufour, YF
    Gonvers, JJ
    Henz, S
    Hermann, R
    Meyenberger, C
    Weitz, M
    Renner, EL
    SWISS MEDICAL WEEKLY, 2003, 133 (33-34) : 455 - 460
  • [34] Daily use of ribavirin-interferon combination in earlier non-responder or relapser patients with chronic hepatitis C.
    Karasu, Z
    Gurakar, A
    Jazzar, A
    McMillon, G
    Hulagu, S
    Wright, H
    HEPATOLOGY, 1999, 30 (04) : 629A - 629A
  • [35] The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan
    Hiramatsu, N
    Kasahara, A
    Nakanishi, F
    Toyama, T
    Tsujii, M
    Tsuji, S
    Kanto, T
    Takehara, T
    Kato, M
    Yoshihara, H
    Naito, M
    Katayama, K
    Hijioka, T
    Hagiwara, H
    Kubota, S
    Oshita, M
    Meren, H
    Masuzawa, M
    Haruna, Y
    Mita, E
    Suzuki, K
    Hayashi, N
    HEPATOLOGY RESEARCH, 2004, 29 (03) : 142 - 147
  • [36] Prolonged interferon treatment after combination interferon and ribavirin therapy in patients with chronic hepatitis C: A clinical trial of interferon relapsers and non-responders
    Kao, JH
    Lai, MY
    Chen, PJ
    Cheng, YM
    Chen, DS
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2001, 100 (10) : 662 - 667
  • [37] Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
    Poynard, T
    Marcellin, P
    Lee, SS
    Niederau, C
    Minuk, GS
    Ideo, G
    Bain, V
    Heathcote, J
    Zeuzem, S
    Trepo, C
    Albrecht, J
    LANCET, 1998, 352 (9138): : 1426 - 1432
  • [38] Which is the most cost-effective combination therapy using interferon alfa-2b plus ribavirin for non-responder patients with chronic hepatitis C?.
    Ricardo, MO
    Carmen, A
    Angel, CM
    Leslie, F
    HEPATOLOGY, 2002, 36 (04) : 577A - 577A
  • [39] Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or standard combination therapy
    Chousterman, N
    Auray-Cartier, V
    Hagege, H
    Arpurt, JP
    Cassan, P
    Denis, J
    Gargot, D
    Nalet, B
    Nouel, O
    Pariente, A
    Wartelle-Bladou, C
    HEPATOLOGY, 2002, 36 (04) : 362A - 362A
  • [40] Efficacy of ribavirin monotherapy following combination therapy with interferon alfa-2b and ribavirin for patients with chronic hepatitis C
    Nagayama, A
    Tanaka, A
    Ankoh, H
    Narita, T
    Izumi, M
    Miyake, K
    Takikawa, H
    HEPATOLOGY RESEARCH, 2005, 32 (02) : 101 - 106
12345